Catalog # PD1-H82A4



Synonym

PDCD1,PD1,CD279,SLEB2

Source

Biotinylated Human PD-1, Mouse IgG2a Fc, Avitag (PD1-H82A4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # <u>Q15116-1</u>).

Predicted N-terminus: Leu 25

Molecular Characterization



This protein carries a mouse IgG2a Fc tag at the C-terminus, followed by an Avi tag (AvitagTM).

The protein has a calculated MW of 44.5 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation

Biotinylation of this product is performed using Avitag[™] technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Biotinylated Human PD-1, Mouse IgG2a Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS



The purity of Biotinylated Human PD-1, Mouse IgG2a Fc,Avitag (Cat. No. PD1-H82A4) is more than 90% and the molecular weight of this protein is around 110-120 kDa verified by SEC-MALS. Report


Bioactivity-ELISA

>>> www.acrobiosystems.com


1/26/2022



Catalog # PD1-H82A4




Immobilized Human PD-L1, Fc Tag (Cat. No. <u>PD1-H5258</u>) at 2 μ g/mL (100 μ L/well) can bind Biotinylated Human PD-1, Mouse IgG2a Fc,Avitag (Cat. No. <u>PD1-H82A4</u>) with a linear range of 5-156 ng/mL (QC tested).



Immobilized Human PD-L2, Fc Tag (Cat. No. <u>PD2-H5251</u>) at 2 μ g/mL (100 μ L/well) can bind Biotinylated Human PD-1, Mouse IgG2a Fc,Avitag (Cat. No. <u>PD1-H82A4</u>) with a linear range of 1-78 ng/mL (Routinely tested).

Background

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.



Immobilized Nivolumab at 2 μ g/mL (100 μ L/well) can bind Biotinylated Human PD-1, Mouse IgG2a Fc,Avitag (Cat. No. <u>PD1-H82A4</u>) with a linear range of 0.2-5 ng/mL (Routinely tested).

Clinical and Translational Updates

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.

>> www.acrobiosystems.com

1/26/2022